What Pfizer, Trump, and consumers got out of a surprising deal — and what they didn’t

WASHINGTON — After months of pledging he would get pharmaceutical companies to lower their prices, President Trump can now say that he pressed the CEO of a major drug maker, Pfizer, to back down on a series of price hikes.

Pfizer, in turn, has earned glowing praise from Trump and his administration and will likely not suffer much, if at all, financially.